
Improving guideline adherent multiple myeloma diagnostics with primary care provider perspectives
Monday, November 17, at 16:00 BST | 17:00 CEST | 11:00 EDT | 8:00 PDT
Multiple Myeloma (MM) is among the cancers having the longest delay from first symptoms to diagnosis. Patients often initially present to their primary care providers (PCPs) and may visit multiple times before being referred to a specialist. Laboratory testing is pivotal in the diagnostic workup, especially in primary care settings where initial investigations often occur.
The College of American Pathologists (CAP) has published guidelines for the laboratory detection and initial diagnosis of monoclonal gammopathies in 2022. Timely diagnosis has been proven to result in fewer complications and improved patient outcomes. Despite significant advancement in the understanding of MM biology and clear guidelines around diagnostic testing, the status of US PCPs’ understanding of MM diagnostic testing practices remain understudied.
This webinar will share the key findings of a national survey of US PCPs, the first of its kind, assessing the awareness of recommended MM diagnostic workup as well as the current approach to MM diagnosis among US PCPs. We will identify opportunities to improve laboratory test ordering practices and enhance patient care.
Join us to advance your understanding and approach to MM diagnosis.
Key learning objectives:
- Understand the importance of timely and guideline-compliant testing for Multiple Myeloma (MM) and related plasma cell disorders.
- Assess the current knowledge and practices of US primary care providers (PCPs) regarding MM diagnostic testing and diagnosis.
- Explore how US PCPs are utilizing laboratory services and identify additional support needed to improve testing and patient care.
- Learn practical steps and frameworks to enhance guideline-compliant MM laboratory test ordering practices.
Who should attend?
Laboratory Professionals, Laboratory Directors/Decision Makers, Medical Directors, Primary Care Providers, Hematologists/Oncologists
Accreditation statement
SelectScience® is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
Speakers

Bhrugu is a distinguished Hematology/Oncology Medical Science Liaison (MSL) with over 15 years of experience in clinical and pre-clinical trial research. Originally from India, he earned his PhD before moving to the United States, where he spent six years as a postdoctoral fellow at Emory University, leading HIV cure research projects. Currently, Bhrugu is an MSL at The Binding Site Inc., focusing on scientific and clinical education, KOL engagement, diagnostic insights, market research, and data analytics. A multi-award-winning scientific communicator, Bhrugu excels in collaborating with Key Opinion Leaders (KOLs), healthcare professionals, clinicians, and stakeholders in oncology and immunology.
Moderator
